Overview

Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection

Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.
Phase:
N/A
Details
Lead Sponsor:
Shi, Patricia, M.D.
Collaborator:
Genzyme, a Sanofi Company
Treatments:
JM 3100
Plerixafor